November 2025 — As the cell and gene therapy (CGT) landscape continues to expand, the need for robust aseptic monitoring and contamination control is growing rapidly. According to a recent industry roundup by BioInformant, Avantor has introduced its next-generation sterile sampling platform to enhance real-time environmental and process monitoring for CGT manufacturing. In parallel, Cellipont Bioservices has entered a collaboration with Ernexa Therapeutics on cell therapy development, while Ajinomoto Bio-Pharma Services is scaling up its peptide and protein production capacity.
Avantor’s platform incorporates high-sensitivity sampling technologies within a GMP-compatible design, providing more frequent and precise contamination checks in viral vector production, cell expansion, and gene-modified cell workflows. This next-generation solution aims to streamline sterility validation and support regulatory submissions with stronger, more consistent data.
Photo by Louis Reed on Unsplash
The Cellipont–Ernexa partnership demonstrates the deepening integration of CDMO-driven development models in CGT, while Ajinomoto’s expansion reinforces its role as a key manufacturing enabler within the cell therapy ecosystem.
Hillgene Perspective
As CGT products advance toward later-stage development and commercial readiness, manufacturing consistency and quality robustness have become central determinants of market success. Hillgene recognizes that upstream quality tools—such as Avantor’s sterile sampling technology—will be pivotal in improving process transparency and risk mitigation. Hillgene continues to invest in modular production units, digitized QC systems, and real-time data traceability to support high-standard CGT manufacturing.
Photo by Toon Lambrechts on Unsplash
Source: BioInformant, Cell Therapy Industry News Round-Up: Avantor, Cellipont, and Ajinomoto expand CGT manufacturing capabilities, November 2, 2025.
86 198 5711 6962 
info@hillgene.com 
English
